BIO-Europe 2007 to Bring out Biotech's Biggest Names and Explore Key Issues for the Industry's Future

EBD Group and the Biotechnology Industry Organization (BIO) today
announce that BIO-Europe 2007 will bring out many of the most well
known and respected names in the biotech industry to confront the key
issues affecting the industry's future. With an anticipated 2000
participants, BIO-Europe 2007 is expected to be the largest
stand-alone biotechnology partnering event ever held.

Key program highlights of BIO-Europe 2007 include:

-- The Changing World Order of Biotech-Pharma - How Will Emerging
Realities Affect Your Business Strategy? Moderated by Vaughn
M. Kailian, General Partner, MPM Capital, and will also
feature Barbara Yanni, Vice President and Chief Licensing
Officer, Merck & Co., Inc., Jan Lundberg, Executive Vice
President, Discovery Research, AstraZeneca, and John
Maraganore, CEO, Alnylam Pharmaceuticals, Inc. These leaders
will discuss the impact of Big Pharma's struggles to meet the
financial world's growth expectations on the up and coming,
higher growth biotech sector.

-- Alternative Financing - Unconventional Routes to Capital. Led
by Dr. Ludger Wess, Managing Partner of akampion, this
interactive workshop tackles the challenge of a capital
marketplace now characterized by fewer life science VC firms
facing more pressure for quick exits.

-- The Trend Toward Early Stage M&A and Licensing - What are the
New Rules to the Dating Game? Dr. Rudiger Herrmann, Partner,
Mayer Brown Rowe & Maw LLP will lead this interactive workshop
exploring the change in the industry toward early stage
projects versus mid- to late-stage in-licensing and M&A
activities.

-- Getting to the New Tipping Point: Proof of Concept. With Phase
III failure rates increasing, the drug industry needs more
products reaching positive proof of concept. That's why the
prices of Phase II deals are rising so sharply (upfronts
increased more than 50% year over year according to
Windhover's Strategic Transactions Database) and why biotechs,
big pharmas and major investors are changing their strategies.
Moderated by Roger Longman, Managing Partner, Windhover
Information, this panel will include Dr. Corinne Savill,
Global Head, Search and Evaluation, Novartis, Dr. Gary A.
Herman, Executive Director, Experimental Medicine, Merck
Research Laboratories and Dr. Paul Stoffels, Company Group
Chairman, Global Research & Development, Pharmaceuticals
Group, Johnson & Johnson.

-- Biotech/Pharma Co-Promotion Rights: An Opportunity or a
Challenge? Led by Gayle Mills, Executive Vice President,
Business Operations, ROXRO PHARMA, Inc., this panel will dive
into co-marketing and co-promotion challenges spurred by the
increased partnering between biotech and pharmaceutical
companies. Featured panellists include Dr. Rob Wills, Vice
President, Alliance Management, Pharmaceuticals Group, Johnson
& Johnson, Louis J. Scotti, Vice President, Marketing and
Business Development, Arena Pharmaceuticals, Inc. and Ben
Bonifant, Vice President, Business Development Practice,
Campbell Alliance.

-- A Day in the Life of Experienced Dealmakers. Now in its 5th
consecutive year, this highly popular and provocative plenary
session promises to continue its tradition of lively and
insightful debate over key issues of strategic deal making by
some of the biggest names in biotech. This session is led by
James Watson, Managing Director and Head of Merchant Banking,
Burrill & Company, joined by Thomas Hofstaetter, Senior Vice
President of Corporate Development, Wyeth and John G. Goddard,
Global Head and Senior VP of Strategic Planning and Business
Development, AstraZeneca.

Other workshops and panels include:

-- What is Translational Medicine and How Can Your Company
Exploit It?

-- US and European Patent Law: Anticipated Changes and the Impact
for the Life Sciences Industry

-- What You Wish You Knew Before Going to Market in the United
States

-- From Target to Clinic - Reduce the Time to Your First
Important Milestone

-- Global Drug Pricing - A Way Out of the Dilemma?

-- How Do Recent Changes Within the FDA Affect Your Company's
Business Strategy?

-- An Experts' View on the State of the Industry

-- Pharma's Franchise View on Novel Medicines for CNS Disease

-- David vs. Goliath - How Can Mid-Size Pharma Compete in an
Environment Dominated by Big Pharma?

-- Beyond Antibodies: Building on Protein Scaffolds

-- Post-Merger Integration - How Best to Leverage Synergies

A complete list of workshops, panels and abstracts can be accessed
at: http://www.ebdgroup.com/bioeurope/program.htm

Notes to Editors:

Entry to BIO-Europe 2007 is free to the media, including full
access to the partnering system, sessions, press conferences,
workshops, and pre-arranged partnering meetings. Visit the BIO-Europe
conference website at http://www.ebdgroup.com/bioeurope/press_reg.htm
for detailed information on this year's conference and online
registration. When you register online, please indicate in the comment
field that you are requesting a complimentary press registration.
Please fax a copy of your press pass to complete your complimentary
media registration to fax number +49 (89) 23 88 756 55.

About BIO-Europe 2007

BIO-Europe 2007 is the preeminent stand-alone partnering event for
the biotechnology industry. Delegates from all parts of the
biotechnology value-chain come to BIO-Europe to efficiently identify,
engage and enter into the strategic relationships that drive their
business successfully forward. It is anticipated that this year's
BIO-Europe partnering event will draw 2,000 industry attendees from
almost 40 countries, representing more than 1,100 companies for three
days of high-level networking. BIO-Europe features the industry's most
advanced web-based partnering system that delegates will use to
generate in excess of 7,000 partnering meetings. BIO-Europe features
an exceptional international exhibition where companies, organizations
and biotech regions can showcase their offerings. Additional
networking opportunities will abound at evening and special events.
BIO-Europe is co-developed by EBD Group and the Biotechnology Industry
Organization, in partnership with European Biopharmaceutical
Enterprises.

About EBD Group

EBD Group International, LLC is the leading partnering firm for
the global biotechnology industry. Since 1993, firms in the life
sciences have leveraged EBD Group's partnering conferences, technology
and services to identify business opportunities and develop strategic
relationships that drive their business. EBD Group's conferences (run
in collaboration with leading industry partners and international
trade associations such as the Biotechnology Industry Organization
(BIO) include BIO-Europe (co-organized with BIO), the preeminent
stand-alone or ex-U.S. partnering conference for the biotechnology
industry; BIO-Europe Spring; the investor conference, BioEquity Europe
(co-organized with BioCentury Publications and BIO); and the
convergent medical technology partnering conference, BioDevice
Partnering. EBD's novel, web-based, partnering software system is also
used at numerous third-party events around the world. Outside of the
conference format, EBD Group's consultants can provide hands-on
assistance for firms seeking to in- or out-license products and
technologies. EBD Group has offices in San Diego, Munich and London.
For more information visit www.ebdgroup.com.

About BIO

BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations
across the United States and 31 other nations. BIO members are
involved in the research and development of healthcare, agricultural,
industrial and environmental biotechnology products. BIO also produces
the annual BIO International Convention, the global event for
biotechnology. www.bio.org.